2025
Evaluating Major Bleeding Risks with Concomitant Use of Direct Oral Anticoagulants and Selective Serotonin Reuptake Inhibitors in Nonvalvular Atrial Fibrillation Patients
Yao S, Kocis P, Murphy T, Hwang W. Evaluating Major Bleeding Risks with Concomitant Use of Direct Oral Anticoagulants and Selective Serotonin Reuptake Inhibitors in Nonvalvular Atrial Fibrillation Patients. Pharmacoepidemiology 2025, 4: 6. DOI: 10.3390/pharma4010006.Peer-Reviewed Original ResearchDirect oral anticoagulantsNonvalvular atrial fibrillationNonvalvular atrial fibrillation patientsVitamin K antagonistsSerotonin reuptake inhibitorsHazard ratioBleeding eventsConcomitant useOral anticoagulantsReuptake inhibitorsFollow-upConfidence intervalsElectronic health recordsEstimate hazard ratiosCause-specific proportional hazards modelDOAC prescriptionsHAS-BLED scoreAtrial fibrillation patientsBaseline CHA2DS2-VASc scoreCHA2DS2-VASc scoreRetrospective cohort studyInverse probability of treatmentHealth recordsProportional hazards modelDrug-drug interactionsPredictors of Venous Thromboembolism Following Geriatric Distal Femur Fracture Fixation: Are These Patients at Higher Risk Compared With Hip Fracture Patients?
Seddio A, Vasudevan R, Gouzoulis M, Jabbouri S, Grauer J, Fram B. Predictors of Venous Thromboembolism Following Geriatric Distal Femur Fracture Fixation: Are These Patients at Higher Risk Compared With Hip Fracture Patients? JAAOS Global Research And Reviews 2025, 9: e24.00246. PMID: 39823200, PMCID: PMC11745856, DOI: 10.5435/jaaosglobal-d-24-00246.Peer-Reviewed Original ResearchConceptsOdds of venous thromboembolismDirect oral anticoagulantsVenous thromboembolismHeightened oddsHFx patientsIncreased odds of VTEPredictors of venous thromboembolismRisk factors of venous thromboembolismIncidence of venous thromboembolismRate of venous thromboembolismAssociated with considerable morbidityAssociated with reduced oddsFactors of venous thromboembolismEffective therapeutic optionIndependent risk factorClinical risk factorsHip fracture patientsRetrospective cohort studyFemur fracture fixationCoagulopathy disordersOral anticoagulantsElixhauser Comorbidity IndexSurgical managementActive cancerDistal femur fracture fixationDirect oral anticoagulants or warfarin in patients with left ventricular thrombus after ST-elevation myocardial infarction: a pilot trial and a prespecified meta-analysis of randomised trials.
Jenab Y, Sadeghipour P, Mohseni-Badalabadi R, Kaviani R, Hosseini K, Pasebani Y, Khederlou H, Rafati A, Mohammadi Z, Jamalkhani S, Talasaz A, Firouzi A, Ariannejad H, Alemzadeh-Ansari M, Ahmadi-Renani S, Maadani M, Farrashi M, Bakhshandeh H, Piazza G, Krumholz H, Mehran R, Lip G, Bikdeli B. Direct oral anticoagulants or warfarin in patients with left ventricular thrombus after ST-elevation myocardial infarction: a pilot trial and a prespecified meta-analysis of randomised trials. EuroIntervention 2025, 21: 82-92. PMID: 39773831, PMCID: PMC11684328, DOI: 10.4244/eij-d-24-00527.Peer-Reviewed Original ResearchConceptsST-elevation myocardial infarctionLeft ventricular thrombusLeft ventricular thrombus resolutionRandomised clinical trialsPooled analysisVentricular thrombusTreatment of left ventricular thrombusTwo-dimensional transthoracic echocardiographyMyocardial infarctionDirect oral anticoagulantsImaging core laboratoryWarfarin-based anticoagulationMeta-analysis of randomised trialsTransthoracic echocardiographyOpen-labelOral anticoagulantsBleeding eventsAdult patientsDOACsCore laboratoryWarfarinClinical trialsRandomised trialsPatientsBleeding
2024
Hereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network
DeSancho M, Suvar E, Roberts J, Tarantino M, Schwartz J, Callis J, Recht M. Hereditary antithrombin deficiency pilot project registry from the American Thrombosis and Hemostasis Network. Journal Of Thrombosis And Haemostasis 2024, 22: 3183-3190. PMID: 39151704, DOI: 10.1016/j.jtha.2024.07.026.Peer-Reviewed Original ResearchConceptsHereditary antithrombin deficiencyLow-molecular-weight heparinVenous thromboembolismOral anticoagulantsAT concentrateAdverse eventsIncreased risk of venous thromboembolismRisk factorsRisk of venous thromboembolismDirect oral anticoagulantsAmerican ThrombosisSeventy-nine patientsDeep vein thrombosisHemostasis NetworkRecurrent thrombosisConcentrate administrationPulmonary embolismAntithrombin deficiencyThrombotic eventsVein thrombosisProspective studyPredominant manifestationArterial thrombosisGlobal RegistryIncreased riskPractical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients
Ranjan S, Leung D, Ghiaseddin A, Taylor J, Lobbous M, Dhawan A, Budhu J, Coffee E, Melnick K, Chowdhary S, Lu‐Emerson C, Kurz S, Burke J, Lam K, Patel M, Dunbar E, Mohile N, Peters K. Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients. Cancer 2024, 130: 1577-1589. PMID: 38288941, DOI: 10.1002/cncr.35220.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsLow-molecular-weight heparinVenous thromboembolismIntracranial hemorrhageBrain tumorsEfficacy of direct oral anticoagulantsMetastatic brain tumor patientsRisk of intracranial hemorrhageTreatment of venous thromboembolismManagement of venous thromboembolismMetastatic brain tumorsOral anticoagulant useTreat venous thromboembolismOff-label useBrain tumor patientsBrain metastasesOral anticoagulantsAnticoagulant useTumor patientsClinical trialsPatientsClinical guidanceThromboembolismGlioblastomaHeparinWhen Direct Oral Anticoagulants Should Not Be Standard Treatment JACC State-of-the-Art Review
Bejjani A, Khairani C, Assi A, Piazza G, Sadeghipour P, Talasaz A, Fanikos J, Connors J, Siegal D, Barnes G, Martin K, Angiolillo D, Kleindorfer D, Monreal M, Jimenez D, Middeldorp S, Elkind M, Ruff C, Goldhaber S, Krumholz H, Mehran R, Cushman M, Eikelboom J, Lip G, Weitz J, Lopes R, Bikdeli B. When Direct Oral Anticoagulants Should Not Be Standard Treatment JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2024, 83: 444-465. PMID: 38233019, DOI: 10.1016/j.jacc.2023.10.038.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsStandard of careRandomized Controlled TrialsOral anticoagulantsAtrial fibrillationCatheter-associated deep vein thrombosisCerebral venous sinus thrombosisControlled TrialsVitamin K antagonistsThrombotic antiphospholipid syndromeEnd-stage renal diseaseLeft ventricular thrombusVenous thromboembolism treatmentVenous sinus thrombosisDeep vein thrombosisRheumatic heart diseaseReview of randomized controlled trialsEvidence-based reviewK antagonistsAntiphospholipid syndromeSinus thrombosisVentricular thrombusVein thrombosisThromboembolism treatmentVenous thrombosis
2023
Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials
Salman R, Stephen J, Tierney J, Lewis S, Newby D, Parry-Jones A, White P, Connolly S, Benavente O, Dowlatshahi D, Cordonnier C, Viscoli C, Sheth K, Kamel H, Veltkamp R, Larsen K, Hofmeijer J, Kerkhoff H, Schreuder F, Shoamanesh A, Klijn C, van der Worp H, Haemorrhage C, Klug D, Casolla B, Puy L, Coffee M, Kuchcinski G, Labreuche J, van Nieuwenhuizen K, Algra A, van Gelder I, Kappelle L, Rinkel G, Schutgens R, Khatri P, Conwit R, Falcone G, Elm J, Anderson C, Song L, Pandian J, Hart R, Sharma M, Aref H, Tarhuni W, Fabregas J, Diener H, Endres M, Lemmens R, Kwon S, Lee B, Ameriso S, Milling T, Kasner S, Mikulik R, Xavier D, Beer R, Toni D, Eckstein J, Seiffge D, Ferro J, Tsivgoulis G, Sharma S, Wei-Liou C, Hohnloser S, Katsanos A, Bosch J, Healey J, Eikelboom J, Khaw A, Gladstone D, Pikula A, Coutts S, Smith E, Butcher K, Field T, Gioia L, Stapf C, Halse O, Ringleb P, Enzinger C, Sibon I, Montaner J, Caso V, Heuschmann P, Lip G, Haefeli W, Debette S, Dennis M, Wyller T, Rønning O, Eilertsen H, Ihle-Hansen H, Sandset E, Pennlert J, Glader E, Kruuse C, Wester P, Carlsson M, Forfang E. Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials. The Lancet Neurology 2023, 22: 1140-1149. PMID: 37839434, DOI: 10.1016/s1474-4422(23)00315-0.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsAdverse cardiovascular eventsSpontaneous intracranial hemorrhageOral anticoagulationCardiovascular eventsIntracranial hemorrhageAtrial fibrillationCardiovascular deathIndividual participant dataEligible trialsHazard ratioPrimary outcomeOngoing trialsFixed-effect inverse variance modelParticipant dataDirect oral anticoagulantsOral anticoagulant agentsCochrane systematic reviewCox regression modelPrevious intracranial hemorrhageInverse variance modelBritish Heart FoundationLong-term useSubgroup of participantsAntiplatelet monotherapy
2022
Spontaneous Adrenal Hemorrhage with Mild Hypoadrenalism in a Patient Anticoagulated with Apixaban for Antiphospholipid Syndrome: A Case Report and Literature Review
Tan J, Shukla A, Hu J, Majumdar S. Spontaneous Adrenal Hemorrhage with Mild Hypoadrenalism in a Patient Anticoagulated with Apixaban for Antiphospholipid Syndrome: A Case Report and Literature Review. Case Reports In Endocrinology 2022, 2022: 6538800. PMID: 36504598, PMCID: PMC9729038, DOI: 10.1155/2022/6538800.Peer-Reviewed Case Reports and Technical NotesDirect oral anticoagulantsAdrenal hemorrhageAntiphospholipid syndromeSafety of DOACsBilateral adrenal hemorrhageDeep venous thrombosesPrimary adrenal insufficiencySpontaneous adrenal hemorrhageCases of patientsPubMed/MEDLINEWarrants further studyAldosterone physiologyAPLS patientsAdrenal involvementEndocrine complicationsOral anticoagulantsVenous thrombosesAdrenal insufficiencyCortisol deficiencyAdrenal functionCortisol replacementAdrenal glandCase reportLaboratory findingsZona reticularisDirect oral anticoagulants in pediatric venous thromboembolism: Experience in specialized pediatric hemostasis centers in the United States
Corrales-Medina F, Raffini L, Recht M, Santos J, Thornburg C, Davila J, Investigators A. Direct oral anticoagulants in pediatric venous thromboembolism: Experience in specialized pediatric hemostasis centers in the United States. Research And Practice In Thrombosis And Haemostasis 2022, 7: 100001. PMID: 36970740, PMCID: PMC10031368, DOI: 10.1016/j.rpth.2022.100001.Peer-Reviewed Original ResearchPrevention of venous thromboembolismVenous thromboembolismOral anticoagulantsPediatric hematologistsClinically relevant nonmajor bleeding eventsTreatment of acute venous thromboembolismSecondary prevention of venous thromboembolismUS Food and Drug Administration approvalFood and Drug Administration approvalRecurrent thrombosis rateDirect oral anticoagulantsAcute venous thromboembolismNonmajor bleeding eventsPediatric venous thromboembolismDrug Administration approvalFemales aged >Prescribed DOACsDOAC useBleeding complicationsBleeding eventsMenstrual bleedingAnticoagulation regimenDOACsAdministration approvalOff-labelDirect Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes Meta-Analysis of Randomized Trials
Khairani C, Bejjani A, Piazza G, Jimenez D, Monreal M, Chatterjee S, Pengo V, Woller S, Cortes-Hernandez J, Connors J, Kanthi Y, Krumholz H, Middeldorp S, Falanga A, Cushman M, Goldhaber S, Garcia D, Bikdeli B. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes Meta-Analysis of Randomized Trials. Journal Of The American College Of Cardiology 2022, 81: 16-30. PMID: 36328154, PMCID: PMC9812926, DOI: 10.1016/j.jacc.2022.10.008.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsVitamin K antagonistsVenous thromboembolic eventsArterial thrombotic eventsSubsequent venous thromboembolic eventsThrombotic antiphospholipid syndromeMajor bleedingThrombotic eventsK antagonistsOral anticoagulantsAntiphospholipid syndromeUse of DOACsMain efficacy outcomeMain safety outcomeCochrane Central RegisterAdequate allocation concealmentRandom-effects modelRandom sequence generationThromboembolic eventsCentral RegisterEfficacy outcomesArterial thrombosisControlled TrialsRandomized trialsAllocation concealmentBody mass index from the RE-LY trial: further evidence of the obesity paradox
Jacobs M, Ezekowitz M, Nagarakanti R, Eikelboom J, Khan O, Reiss J, Liu H, McAndrew T, Francese D, Arce J, Brueckmann M, Connolly S, Yusuf S. Body mass index from the RE-LY trial: further evidence of the obesity paradox. European Heart Journal 2022, 43: ehac544.629. DOI: 10.1093/eurheartj/ehac544.629.Peer-Reviewed Original ResearchBody mass indexDirect oral anticoagulantsRE-LY trialObesity paradoxMajor bleedingIntracranial hemorrhageSystemic embolismIschemic strokeDrug assignmentMass indexResults Body mass indexHigher Body Mass IndexWorld Health Organization criteriaCox proportional hazards modelIntracranial hemorrhage rateIschemic stroke rateRates of diabetesProportional hazards modelContinuous variablesLower ratesPrior strokeOral anticoagulantsRE-LYBaseline characteristicsCreatinine clearanceClinical and neuroimaging risk factors associated with the development of intracerebral hemorrhage while taking direct oral anticoagulants
Das A, Gökçal E, Regenhardt R, Warren A, Biffi A, Goldstein J, Kimberly W, Viswanathan A, Schwamm L, Rosand J, Greenberg S, Gurol M. Clinical and neuroimaging risk factors associated with the development of intracerebral hemorrhage while taking direct oral anticoagulants. Journal Of Neurology 2022, 269: 6589-6596. PMID: 35997817, PMCID: PMC10947801, DOI: 10.1007/s00415-022-11333-2.Peer-Reviewed Original ResearchConceptsCortical superficial siderosisPrior ischemic strokeDOAC usersCerebral microbleedsWhite matter hyperintensitiesIschemic strokeSevere white matter hyperintensitiesOral anticoagulant usageDirect oral anticoagulantsSingle referral centerHigh hemorrhagic riskCoronary artery diseaseAge-matched controlsMultivariable regression modelsDOAC therapyICH cohortPrior strokeOral anticoagulantsSuperficial siderosisBaseline demographicsReferral centerSmoking historyArtery diseaseConclusionsRisk factorsHemorrhage riskLeft Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation : A Decision Analysis.
Chew DS, Zhou K, Pokorney SD, Matchar DB, Vemulapalli S, Allen LA, Jackson KP, Samad Z, Patel MR, Freeman JV, Piccini JP. Left Atrial Appendage Occlusion Versus Oral Anticoagulation in Atrial Fibrillation : A Decision Analysis. Annals Of Internal Medicine 2022, 175: 1230-1239. PMID: 35969865, DOI: 10.7326/m21-4653.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsHigh bleeding riskLower stroke riskClinical effectiveness dataAtrial fibrillationBleeding riskStroke riskOral anticoagulantsIschemic strokeEffectiveness dataHAS-BLED scoreIndividual riskHigh stroke riskMajor bleeding riskNonvalvular atrial fibrillationPatient's individual riskPrimary end pointAtrial appendage occlusionBase-case analysisOral anticoagulationPrior strokeVASc scoreStroke preventionWatchman deviceAppendage occlusionDirect Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis
Yaghi S, Saldanha IJ, Misquith C, Zaidat B, Shah A, Joudi K, Persaud B, Khalek F, Shu L, de Havenon A, Mistry EA, Bakradze E, Goldstein ED, Reagan J, Theodorou A, Palaiodimou L, Furie K, Field TS, Tsivgoulis G, Mac Grory B. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Cerebral Venous Thrombosis: A Systematic Review and Meta-Analysis. Stroke 2022, 53: 3014-3024. PMID: 35938419, DOI: 10.1161/strokeaha.122.039579.Peer-Reviewed Original ResearchConceptsCerebral venous thrombosisDirect oral anticoagulantsVitamin K antagonistsVenous thrombosisK antagonistsSystematic reviewRelative riskObservational studyDirect Oral Anticoagulants Versus Vitamin K AntagonistsSafety of DOACsVitamin K antagonist treatmentRecurrent venous thromboembolismHigh-level evidenceLeast moderate riskVenous recanalizationOral anticoagulantsVenous thromboembolismMajor hemorrhageMore patientsAntagonist treatmentIntracranial hemorrhageCombination of keywordsComparable efficacyInclusion criteriaSafety outcomesEfficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants
Bikdeli B, Tajrishi F, Sadeghipour P, Talasaz AH, Fanikos J, Lippi G, Siegal DM, Eikelboom JW, Monreal M, Jimenez D, Connors JM, Ageno W, Barnes GD, Piazza G, Angiolillo DJ, Parikh SA, Kirtane AJ, Lopes RD, Bhatt DL, Weitz JI, Mehran R, Krumholz HM, Goldhaber SZ, Lip GYH. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. JAMA Cardiology 2022, 7: 747-759. PMID: 35648414, DOI: 10.1001/jamacardio.2022.1292.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsRandomized clinical trialsAcute VTE treatmentDose adjustmentOral anticoagulantsLow-intensity treatmentPrimary preventionLarge registriesVTE treatmentHigh-risk medical patientsStable atherosclerotic vascular diseaseHigh-risk cancer patientsLarge randomized clinical trialsSecondary VTE preventionPeripheral artery diseaseAtherosclerotic vascular diseaseDaily clinical practiceRoutine practice patternEvidence of safetyRecent revascularizationStroke preventionVTE preventionArtery diseaseMedical patientsCancer patientsPharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study
Nakazaki M, Oka S, Magota H, Kiyose R, Onodera R, Ukai R, Kataoka-Sasaki Y, Sasaki M, Honmou O. Pharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study. Journal Of Stroke And Cerebrovascular Diseases 2022, 31: 106520. PMID: 35523052, DOI: 10.1016/j.jstrokecerebrovasdis.2022.106520.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsPlatelet aggregation testCardioembolic strokePlatelet aggregationFXa inhibitorsOral anticoagulantsStroke patientsPharmacological differencesAdenosine diphosphateAggregation testConcurrent antiplatelet therapyIschemic stroke patientsCardioembolic stroke patientsOnset of symptomsResults Six patientsLight transmission aggregometryFactor Xa inhibitorsAntiplatelet therapySecondary preventionSix patientsAntiplatelet drugsAtrial fibrillationAntiplatelet effectXa inhibitorsDabigatranAmerican College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period
Abraham NS, Barkun AN, Sauer BG, Douketis J, Laine L, Noseworthy PA, Telford JJ, Leontiadis GI. American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. The American Journal Of Gastroenterology 2022, 117: 542-558. PMID: 35297395, PMCID: PMC8966740, DOI: 10.14309/ajg.0000000000001627.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDirect oral anticoagulantsP2Y12 receptor inhibitorsAcute gastrointestinal bleedingProthrombin complex concentrateSecondary preventionAcetylsalicylic acidGastrointestinal bleedingPCC administrationReceptor inhibitorsTemporary interruptionEndoscopy settingTarget patientsGastroenterology Clinical Practice GuidelineFresh frozen plasma administrationAdministration of idarucizumabManagement of anticoagulantsDual antiplatelet therapyAcute GI bleedingGrading of RecommendationsClinical practice guidelinesFresh frozen plasmaAcute GIASA monotherapyPeriendoscopic managementAntiplatelet therapyAmerican College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period
Abraham NS, Barkun AN, Sauer BG, Douketis J, Laine L, Noseworthy PA, Telford JJ, Leontiadis GI. American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. Journal Of The Canadian Association Of Gastroenterology 2022, 5: 100-101. PMID: 35368325, PMCID: PMC8972207, DOI: 10.1093/jcag/gwac010.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsDirect oral anticoagulantsAcute gastrointestinal bleedingProthrombin complex concentrateSecondary preventionAcetylsalicylic acidGastrointestinal bleedingPCC administrationReceptor inhibitorsTemporary interruptionEndoscopy settingTarget patientsGastroenterology Clinical Practice GuidelineFresh frozen plasma administrationAdministration of idarucizumabManagement of anticoagulantsDual antiplatelet therapyAcute GI bleedingGrading of RecommendationsClinical practice guidelinesFresh frozen plasmaAcute GIASA monotherapyPeriendoscopic managementAntiplatelet therapyGI bleedingWomen's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment
Bikdeli B, Khairani CD, Barns BM, Rosovsky RP, Jimenez D, Monreal M, Sylvester KW, Middeldorp S, Bates SM, Krumholz HM, Goldhaber SZ, Hunt BJ, Piazza G. Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. Contemporary Clinical Trials 2022, 115: 106714. PMID: 35202841, DOI: 10.1016/j.cct.2022.106714.Peer-Reviewed Original ResearchDirect Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study
Yaghi S, Shu L, Bakradze E, Salehi Omran S, Giles JA, Amar JY, Henninger N, Elnazeir M, Liberman AL, Moncrieffe K, Lu J, Sharma R, Cheng Y, Zubair AS, Simpkins AN, Li GT, Kung JC, Perez D, Heldner M, Scutelnic A, Seiffge D, Siepen B, Rothstein A, Khazaal O, Do D, Kasab S, Rahman LA, Mistry EA, Kerrigan D, Lafever H, Nguyen TN, Klein P, Aparicio H, Frontera J, Kuohn L, Agarwal S, Stretz C, Kala N, El Jamal S, Chang A, Cutting S, Xiao H, de Havenon A, Muddasani V, Wu T, Wilson D, Nouh A, Asad SD, Qureshi A, Moore J, Khatri P, Aziz Y, Casteigne B, Khan M, Cheng Y, Mac Grory B, Weiss M, Ryan D, Vedovati MC, Paciaroni M, Siegler JE, Kamen S, Yu S, Leon Guerrero C, Atallah E, De Marchis GM, Brehm A, Dittrich T, Psychogios M, Alvarado-Dyer R, Kass-Hout T, Prabhakaran S, Honda T, Liebeskind DS, Furie K. Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study. Stroke 2022, 53: 728-738. PMID: 35143325, DOI: 10.1161/strokeaha.121.037541.Peer-Reviewed Original ResearchConceptsCerebral venous thrombosisDirect oral anticoagulantsVenous thrombosisRecurrent venous thrombosisMajor hemorrhageInclusion criteriaDirect Oral Anticoagulants Versus WarfarinMulticenter international retrospective studyInverse probabilityInternational retrospective studySystemic venous thrombosisFavorable safety profileCox regression modelMulticenter international studyAnalysis inclusion criteriaBaseline imaging dataCVT patientsOral anticoagulationComplete recanalizationDOAC treatmentOral anticoagulantsRadiological outcomesRadiographic outcomesVersus WarfarinWarfarin treatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply